Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

apotex nz ltd - risperidone 1mg;   - film coated tablet - 1 mg - active: risperidone 1mg   excipient: hyprolose hypromellose lactose monohydrate macrogol 8000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - apo-risperidone is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

apotex nz ltd - risperidone 2mg;   - film coated tablet - 2 mg - active: risperidone 2mg   excipient: hyprolose hypromellose lactose monohydrate macrogol 8000 magnesium stearate maize starch microcrystalline cellulose sunset yellow aluminium lake titanium dioxide - apo-risperidone is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

apotex nz ltd - risperidone 3mg;  ;   - film coated tablet - 3 mg - active: risperidone 3mg     excipient: hyprolose hypromellose iron oxide yellow lactose monohydrate macrogol 8000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide   - apo-risperidone is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

apotex nz ltd - risperidone 4mg - film coated tablet - 4 mg - active: risperidone 4mg excipient: hyprolose hypromellose indigo carmine iron oxide red lactose monohydrate macrogol 8000 magnesium stearate maize starch microcrystalline cellulose titanium dioxide - apo-risperidone is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

genus pharmaceuticals limited - apomorphine hydrochloride - solution for infusion - 5 mg/ml

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

apotex nz ltd - riluzole 50mg - film coated tablet - 50 mg - active: riluzole 50mg excipient: calcium hydrogen phosphate dihydrate croscarmellose sodium hypromellose macrogol 8000 magnesium stearate microcrystalline cellulose purified talc purified water titanium dioxide - riluzole is indicated for the treatment of patients with amyotrophic lateral sclerosis (als).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - apomorphine hydrochloride hemihydrate, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium chloride; hydrochloric acid; water for injections - indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - apomorphine hydrochloride hemihydrate, quantity: 50 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; hydrochloric acid - movapo pfs is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine injection should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atomoxetine hydrochloride -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atomoxetine hydrochloride -